The Resources to Prevent Youth Vaping Act increases and restructures FDA tobacco user fees to include all tobacco products, including e-cigarettes, while mandating enhanced transparency regarding regulatory expenditures and youth prevention efforts.
Jeanne Shaheen
Senator
NH
The Resources to Prevent Youth Vaping Act increases and restructures FDA user fees for tobacco manufacturers to ensure all tobacco products, including e-cigarettes, contribute to regulatory costs. The bill also mandates enhanced reporting on how these funds are utilized, specifically requiring the FDA to demonstrate how fee revenue supports public education campaigns aimed at preventing youth vaping.
The Resources To Prevent Youth Vaping Act is a major overhaul of how the FDA funds its tobacco oversight. For years, traditional tobacco companies (think cigarettes and cigars) have footed the bill for FDA regulation through user fees, while many e-cigarette manufacturers have essentially had a free ride. This bill changes that by hiking the total annual fees the FDA collects to $712 million through 2026, jumping to over $826 million in 2027, and then indexing that amount to inflation every year after. Most importantly, it ends the exemption for vaping products by 2029, ensuring that the companies selling e-cigarettes finally start paying into the system that regulates them.
Starting in fiscal year 2029, the bill moves away from only taxing 'traditional' tobacco. The FDA will be required to develop a new formula that loops in all regulated tobacco products, including e-cigarettes and other electronic nicotine delivery systems. If you’re a manufacturer or importer, your bill will be based on your slice of the market—specifically, your percentage of total U.S. sales from the previous year. To make sure nobody is fudging the numbers, the bill mandates strict sales reporting. Companies will have to start handing over detailed gross domestic sales data by March 2028, moving to a monthly reporting schedule shortly after. This ensures that a massive vape corporation pays significantly more than a smaller, niche importer (Section 2).
For those of us wondering where all that money actually goes, the bill adds some much-needed transparency to the FDA’s checkbook. Starting in 2027, the FDA has to include a specific breakdown in its annual reports showing exactly how much was spent on 'deemed' products (vapes) versus traditional combustibles. They also have to prove that they are putting enough money into public education campaigns to warn teens about the dangers of nicotine. It’s essentially a requirement for the agency to show its work, ensuring that the fees collected from the industry are actually being used to combat the youth vaping crisis they helped create (Section 3).
While the bill doesn't directly tax consumers at the register, the financial impact on the industry is significant. Manufacturers and importers of e-cigarettes will face a new, permanent overhead cost that didn't exist before. For a mid-sized vaping company, this means hiring compliance staff to handle the new monthly sales reporting and budgeting for quarterly fee payments to the FDA. While this might lead to slightly higher prices for adult vapers, the trade-off written into the bill is a more robustly funded regulatory system and a clearer paper trail on how the government is protecting the next generation from nicotine addiction.